Kenvue Inc. $KVUE Shares Sold by Alyeska Investment Group L.P.

Key Points

• Alyeska Investment Group L.P. reduced its position in Kenvue Inc. by 24.1% during the first quarter, selling 1,403,254 shares and owning approximately 0.23% of the company post-sale.
• Kenvue reported $0.29 earnings per share for the quarter, slightly beating analyst estimates of $0.28, despite revenue declining 4.0% compared to the same quarter last year.
• The company recently increased its quarterly dividend to $0.2075 per share, resulting in an annualized dividend yield of 4.0%.

Alyeska Investment Group L.P. lessened its stake in Kenvue Inc. (NYSE:KVUE - Free Report) by 24.1% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,417,559 shares of the company's stock after selling 1,403,254 shares during the period. Alyeska Investment Group L.P. owned 0.23% of Kenvue worth $105,933,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently bought and sold shares of the stock. Evergreen Wealth Solutions LLC boosted its stake in Kenvue by 2.6% in the first quarter. Evergreen Wealth Solutions LLC now owns 16,769 shares of the company's stock valued at $402,000 after acquiring an additional 432 shares in the last quarter. Fulton Bank N.A. boosted its stake in Kenvue by 0.6% in the first quarter. Fulton Bank N.A. now owns 78,888 shares of the company's stock valued at $1,892,000 after acquiring an additional 465 shares in the last quarter. Scott & Selber Inc. boosted its stake in Kenvue by 0.4% in the first quarter. Scott & Selber Inc. now owns 106,621 shares of the company's stock valued at $2,557,000 after acquiring an additional 475 shares in the last quarter. Wealth Alliance LLC boosted its stake in Kenvue by 1.6% in the first quarter. Wealth Alliance LLC now owns 31,778 shares of the company's stock valued at $762,000 after acquiring an additional 486 shares in the last quarter. Finally, Everett Harris & Co. CA boosted its stake in Kenvue by 1.4% in the first quarter. Everett Harris & Co. CA now owns 36,971 shares of the company's stock valued at $887,000 after acquiring an additional 500 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company's stock.

Kenvue Stock Performance

NYSE:KVUE traded down $1.91 during mid-day trading on Friday, reaching $18.64. The stock had a trading volume of 135,326,130 shares, compared to its average volume of 13,801,933. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.68 and a current ratio of 0.98. The firm has a market capitalization of $35.76 billion, a price-to-earnings ratio of 25.18, a PEG ratio of 2.95 and a beta of 0.83. Kenvue Inc. has a twelve month low of $17.15 and a twelve month high of $25.17. The business has a 50 day simple moving average of $21.37 and a 200 day simple moving average of $22.38.

Kenvue (NYSE:KVUE - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The company reported $0.29 EPS for the quarter, beating analysts' consensus estimates of $0.28 by $0.01. The firm had revenue of $3.84 billion during the quarter, compared to the consensus estimate of $3.94 billion. Kenvue had a net margin of 9.37% and a return on equity of 20.06%. The firm's revenue was down 4.0% compared to the same quarter last year. During the same quarter last year, the firm earned $0.32 earnings per share. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. On average, analysts expect that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, August 27th. Investors of record on Wednesday, August 13th were given a $0.2075 dividend. The ex-dividend date was Wednesday, August 13th. This is an increase from Kenvue's previous quarterly dividend of $0.21. This represents a $0.83 dividend on an annualized basis and a yield of 4.5%. Kenvue's payout ratio is 112.16%.

Analyst Upgrades and Downgrades

KVUE has been the subject of several research analyst reports. Zacks Research upgraded shares of Kenvue to a "strong sell" rating in a research note on Monday, August 11th. Royal Bank Of Canada decreased their target price on shares of Kenvue from $24.00 to $22.00 and set a "sector perform" rating for the company in a research note on Friday, August 8th. Canaccord Genuity Group lowered their price target on Kenvue from $29.00 to $26.00 and set a "buy" rating on the stock in a report on Friday, August 8th. Citigroup lowered their price target on Kenvue from $24.50 to $22.00 and set a "neutral" rating on the stock in a report on Tuesday, July 15th. Finally, Bank of America lowered their price target on Kenvue from $27.00 to $25.00 and set a "buy" rating on the stock in a report on Tuesday, July 15th. Five analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus price target of $24.38.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.